0.3207 -0.167 (-34.28%) | 02-12 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.45 | 1-year : | 0.53 |
Resists | First : | 0.38 | Second : | 0.45 |
Pivot price | 0.27 | |||
Supports | First : | 0.24 | Second : | 0.15 |
MAs | MA(5) : | 0.34 | MA(20) : | 0.26 |
MA(100) : | 0.51 | MA(250) : | 0.92 | |
MACD | MACD : | 0 | Signal : | -0.1 |
%K %D | K(14,3) : | 90 | D(3) : | 89.6 |
RSI | RSI(14): 63 | |||
52-week | High : | 1.63 | Low : | 0.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NVIV ] has closed below upper band by 10.9%. Bollinger Bands are 5.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.39 - 0.39 | 0.39 - 0.39 |
Low: | 0.37 - 0.37 | 0.37 - 0.37 |
Close: | 0.37 - 0.37 | 0.37 - 0.37 |
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Wed, 07 Feb 2024
Invivo Therapeutics Holdings Faces Nasdaq Delisting - TipRanks.com - TipRanks
Tue, 06 Feb 2024
Bob Langer-founded device-maker declares bankruptcy - Boston Business Journal - The Business Journals
Tue, 06 Feb 2024
Why Is InVivo Therapeutics (NVIV) Stock Up 61% Today? - InvestorPlace
Fri, 02 Feb 2024
InVivo Therapeutics Files for Chapter 11 Bankruptcy - TipRanks.com - TipRanks
Thu, 09 Mar 2023
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury - Business Wire
Thu, 09 Mar 2023
Why InVivo Therapeutics Shares Are Plunging Today - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 3 (M) |
Shares Float | 3 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 3.4 (%) |
Shares Short | 18 (K) |
Shares Short P.Month | 0 (K) |
EPS | -3.28 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 2.86 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -53.8 % |
Return on Equity (ttm) | -98.2 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -3.16 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -10 (M) |
Levered Free Cash Flow | -7 (M) |
PE Ratio | -0.12 |
PEG Ratio | 0 |
Price to Book value | 0.12 |
Price to Sales | 0 |
Price to Cash Flow | -0.12 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |